In this study, we showed that HMGCS2 downregulation decreased the antiproliferative and anti-migratory effects of sorafenib in HCC cells (Figure 6), while additional ketone (β-HB) supplementation enhanced the cytotoxicity of sorafenib toward HCC cells. This evidence concerns the gene HMGCS2 and hepatocellular carcinoma.